Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation
2019 · Nature Communications · 186 citations
https://doi.org/10.1038/s41467-018-08201-x
T
Tiffany Tate
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
29
Papers
1.2K
Citations
13
h-index
15
i10-index
Tiffany Tate is an academic researcher from Columbia University Irving Medical Center. The author has contributed to research in topics: Hematopoietic Stem Cell Transplantation & Epigenetics and DNA Methylation & Bladder and Urothelial Cancer Treatments. The author has an h-index of 13, co-authored 25 publications.
ORCID: 0000-0003-1985-7920Papers by this author
worksRosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
2024 · Nature Communications · 20 citations
https://doi.org/10.1038/s41467-024-50678-2
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
2024 · Cell stem cell · 14 citations
https://doi.org/10.1016/j.stem.2024.10.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat